RBMY1E

Across TCGA pan-cancer cohorts, RBMY1E Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RBMY1E data layer compared with 8 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RBMY1E Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMY1E expression acts as an unfavorable survival marker.

GBM are the cancer types where RBMY1E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.066	0.257	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

RBMY1E–GBM (DFS)

Open the GBM breakdown →